BTIG analyst Tim Chiang weighs in on Synergy Pharmaceuticals Inc (NASDAQ:SGYP), following recent data that showed strong growth in weekly prescriptions for Trulance, the company’s chronic …
In a research report released Thursday, Cantor analyst William Tanner initiated coverage on shares of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) with an Overweight rating and price target …
Analysts from J.P.
Believing Synergy Pharmaceuticals Inc’s (NASDAQ:SGYP) odds in the IBS-C competitive arena just got better, Rodman & Renshaw analyst Ram Selvaraju reiterates a Buy …
Canaccord analyst John Newman is out today with a research note on shares of Synergy Pharmaceuticals Inc (NASDAQ:SGYP), noting that early prescription trends are encouraging for …
During the recently-concluded Digestive Disease Week (DDW) conference held May 6-9 in Chicago, Synergy Pharmaceuticals Inc (NASDAQ:SGYP) presented additional data from the previously-announced …
Canaccord analyst John Newman weighs in with a few insights on Synergy Pharmaceuticals Inc (NASDAQ:SGYP), after Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), the main competitor for SGYP’s …
With CytRx Corporation (NYSE:CYTR) shares on the move and Synergy Pharmaceuticals Inc (NASDAQ:SGYP) raring up for a strategically executed launch for its CIC drug …
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) shares are rising almost 3% today after the biotech firm made waves filing the supplemental New Drug Application (sNDA) …
Yesterday, Synergy Pharmaceuticals Inc (NASDAQ:SGYP) reported fourth-quarter financial results and reiterated the launch of Trulance (plecanatide), Synergy’s recently-approved lead drug, for treatment of chronic …
